Quality of life of patients subjected to specific allergen immunotherapy

Authors

  • Barbara Kubik Department of Nursing, Institute of Health Sciences, State Higher Vocational School in Tarnow, Poland
  • Urszula Romanowska Department of Nursing, Institute of Health Sciences, State Higher Vocational School in Tarnow, Poland
  • Elżbieta Bednarz Department of Nursing, Institute of Health Sciences, State Higher Vocational School in Tarnow, Poland

DOI:

https://doi.org/10.5604/01.3001.0010.7589

Keywords:

allergy, allergens, specific immunotherapy, quality of life

Abstract

Introduction: At present, allergic diseases are some of the most common chronic diseases affecting all spheres of human life. The only form of causative treatment of allergic diseases, apart from elimination of the sensitizing factor, is the specific allergen immunotherapy. The symptoms of allergic diseases can cause a number of consequences, including reduction of patient activity, negatively affect social relationships, ways of spending free time, and also cause sleep disorders. Assessing the quality of life in allergic diseases provides us with knowledge of the patient’s psychological and social functioning, and is a valuable addition to the review of the effectiveness of treatment for allergic diseases, allowing us to assess the patient’s overall well-being.
Aim of the study: The aim of the study was to evaluate the quality of life of patients using specific allergen immunotherapy.
Material and methods: 128 subjects were included in the study, but 100 questionnaires were used for the analysis. The study group was comprised of patients undergoing specific allergen immunotherapy over the age of 18 years. In this paper a diagnostic survey was used as a research method. The tools used are the standard questionnaire SF-36 and the questionnaire survey.
Results: In the present study, it was observed that the overall quality of life of people affected by allergic diseases, as measured by the SF-36 questionnaire, can be assessed as quite good. Respondents subjected to specific allergen immunotherapy consider this method of treatment positively influencing their health as they reduce the symptoms of allergies. As many as 91% of the respondents think that specific immunotherapy affects them to reduce the symptoms of allergies. It has also been shown that the length of therapy has no effect on reducing the symptoms of allergies.
Conclusions: The overall quality of life of patients is quite good, best evaluated in the domains of physical fitness, limitation of activity caused by emotional problems and changes in health status. Researchers positively evaluate the effect of immunotherapy on their health as it reduces the symptoms of allergies. Respondents have little knowledge about how to prevent exposure to allergens. Despite a positive assessment of the effectiveness of immunotherapy, the vast majority of respondents feel the need for additional antihistamines.

Downloads

Download data is not yet available.

References

Samoliński B., Raciborski F., Lipiec A. i wsp. Epidemiologia Chorób Alergicznych w Polsce (ECAP). Alergologia Polska – Pol J Allergology, 2014, 1(1), 10-18.

Ziętkowska E., Ziętkowski Z., Bodzenta-Łukaszyk A. Udział pielęgniarki w diagnostyce chorób alergicznych - testy skórne. Prob Pielęg, 2010, 18(4), 523-528.

Kruszewski J. Alergologia – postępy 2014. Med Prakt, 2015, 5(291), 67-73.

Pawliczak R. Alergologia kompendium. Wydawnictwo Medyczne Termedia, Poznań, 2013, 105-270.

Szczeklik A. Choroby wewnętrzne. Medycyna praktyczna, Kraków, 2006, 1813-1869.

Pietrzyk J.J. Vademecum pediatry. Wydawnictwo Uniwersytetu Jagiellońskiego, Kraków, 2011, 281-285.

Kucharczyk A., Faber K., Jahnz-Różyk K. Alergologia współczesna. 2005, 1(15), 34.

Kilanowicz M., Cegła B., Bartuzi Z. Czy jakość życia zależna od stanu zdrowia jest dobrym markerem badawczym w ocenie postępowania terapeutycznego w schorzeniach alergicznych?. Pielęg XXI w, 2006, 3(16), 97-101.

Kruszewski J., Nowicki R., Śpiewak R. Pokrzywki rozpoznanie i leczenie. Med Prakt, 2011, 87-88.

Cegła B. Ocena jakości życia pacjentów zainfekowanych bakterią Halicobacter pylori przed i po jej eradykacji. Praca doktorska, Collegium Medium, Bydgoszcz, 2005, 50.

Trojanowska A. Znaczenie badań nad jakością życia w medycynie. Zdrowie Publiczne, 2011,121(1), 99-103.

Jahnz-Różyk K. Problemy w alergologii: od teorii do praktyki. Wydanie jubileuszowe Alergologii współczesnej, Warszawa, 2011, 71-84.

Samoliński B. Epidemiologia alergii i astmy w Polsce — doniesienie wstępne badania ECAP. Terapia, 2008, 208, 127–131.

Kowalski M. Immunoterapia alergenowi. Wydawnictwo Mediton, Łódź, 2006, 11-149.

Hofman T. Immunoterapia całoroczna preparatem Allergovit, [Dostępne pod adresem: http://nexter.pl/alergologia_wspolczesna/index.php?action=6_2&rco=6]

Uchmanowicz I., Jankowska-Polańska B., Bronowicka A., i wsp. Determinanty jakości życia chorych na astmę oskrzelową, Nursing Topics, 2013, 21(4), 443–451.

Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol, 2000, 106(2), 253-259.

Hejjaoui A, Knani H, Dhivert F.B. et al. Duration of efficacy of specific immunotherapy with standardized mite extract after its cessation. J All Clin Immunol, 1992, 89, 319.

Farnik-Brodzińska M., Pierzchała W. Badania jakości życia jako ocena skuteczności leczenia chorób alergicznych. Alergologia współczesna, 2002, 10, 5-9.

Grevers G., Rocken M. Ilustrowany podręcznik chorób alergicznych. Wydawnictwo Urban&Partner, Wrocław, 2009, 43-121.

Downloads

Published

2017-12-28

Issue

Section

Original article

How to Cite

Kubik, B., Romanowska, U., & Bednarz, E. (2017). Quality of life of patients subjected to specific allergen immunotherapy. Health Promotion & Physical Activity, 1(1), 47-57. https://doi.org/10.5604/01.3001.0010.7589